Naltrexone’s plasma half-life is commonly listed as about 4 hours, but that figure tells only part of the story. The drug’s primary active metabolite, 6-β-naltrexol, hangs around for roughly 12 to 13 hours, and naltrexone’s grip on opioid receptors in the brain persists far longer than either number would suggest. Understanding why there are multiple “half-lives” floating around for a single medication matters if you take naltrexone for alcohol dependence, opioid use disorder, or an off-label condition like chronic pain.
Why You Will Find More Than One Number
If you search for naltrexone’s half-life, you will encounter figures ranging from 4 hours all the way to 96 hours, depending on the source. None of them are wrong; they just measure different things. The roughly 4-hour figure describes the initial decline of naltrexone itself from the bloodstream after you swallow a tablet. A classic pharmacokinetic study reported a somewhat longer elimination half-life of about 10 hours after an acute oral dose, shrinking slightly to around 9.7 hours with chronic daily use.1PubMed. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing That same study found peak naltrexone blood levels about one hour after dosing, with peak levels of its main metabolite arriving about an hour later.
A widely cited low-dose naltrexone review puts the parent drug’s half-life at 4 hours and the metabolite’s at 13 hours.2PubMed Central. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization The spread between these estimates reflects differences in study design, dosing, and which phase of the drug’s clearance curve researchers focused on. In practice, the fast plasma clearance components fall somewhere in the 4-to-12-hour window.3PubMed. Duration of occupancy of opiate receptors by naltrexone What matters for most people is not which exact number is “correct” but the practical implication: the drug leaves the blood within hours, the metabolite lingers for roughly half a day, and the biological effect on your opioid receptors lasts much longer still.
The Active Metabolite That Extends the Drug’s Reach
Your liver converts more than 98 percent of each naltrexone dose into metabolites, the most important of which is 6-β-naltrexol.2PubMed Central. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization This metabolite is not just an inert byproduct waiting to be excreted. It has its own antagonist activity at opioid receptors, and because its half-life is roughly 12 to 13 hours, it continues blocking receptors well after naltrexone itself has been cleared. In the original pharmacokinetic work, peak blood levels of 6-β-naltrexol were actually about double those of naltrexone, reaching roughly 87 ng/ml compared to naltrexone’s roughly 44 ng/ml.1PubMed. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing So the metabolite is not a minor player; it is present in higher concentrations and sticks around longer than the parent drug.
This is one reason why a single daily dose of 50 mg can maintain effective opioid blockade for 24 hours even though naltrexone itself vanishes from the blood well before the next pill. The metabolite fills the gap. Interestingly, the extent to which any individual converts naltrexone to 6-β-naltrexol varies quite a bit, in part because of genetic differences in the liver enzyme responsible for the conversion.
Receptor Blockade Lasts Much Longer Than Blood Levels Suggest
Here is where naltrexone’s pharmacology gets genuinely surprising. Using positron-emitting radioactive tracers to image the brain, researchers measured how long naltrexone actually sits on opioid receptors after a standard 50 mg dose. The half-time of that receptor blockade ranged from 72 to 108 hours, or roughly three to four and a half days.3PubMed. Duration of occupancy of opiate receptors by naltrexone That is dramatically longer than the fast plasma clearance phase. The researchers noted that a 50 mg daily dose produces blood levels well above what is needed to saturate opioid receptors, so even as plasma concentrations drop, enough drug remains bound in the brain to keep receptors occupied.
The 72-to-108-hour receptor half-time actually lines up with a slower, terminal phase of plasma naltrexone clearance that has a half-life of about 96 hours. This terminal phase is typically too small to measure cleanly in routine blood draws, but it appears to correspond to drug slowly releasing from tissue stores, including the brain. The practical takeaway is that if you miss a single dose, your receptor blockade does not suddenly vanish. But this also means that if you need emergency opioid-based pain relief after stopping naltrexone, the blockade may linger for several days even though a standard blood test would show little or no drug remaining.3PubMed. Duration of occupancy of opiate receptors by naltrexone
How the Liver Processes Naltrexone
Naltrexone’s metabolic pathway is unusual compared to many drugs. It is not processed by the cytochrome P450 enzyme system, which handles the majority of prescription medications. Instead, naltrexone undergoes reduction by dihydrodiol dehydrogenase enzymes in the liver to form 6-β-naltrexol, which is then packaged for excretion in urine.4Harvard Review of Psychiatry. Medication-Assisted Treatment of Opioid Use Disorder This distinction matters because it means naltrexone is less prone to the drug-drug interactions that plague medications metabolized by CYP450 enzymes. You can generally take naltrexone alongside SSRIs, blood pressure medications, and many other common prescriptions without worrying that one drug will speed up or slow down the other’s clearance.
There is a wrinkle, though. One of the dihydrodiol dehydrogenase enzymes involved in this conversion, known as DD4, is genetically variable. Some people carry variants that reduce the enzyme’s activity, which could shift the balance between how much naltrexone versus 6-β-naltrexol circulates in their blood.5PubMed Central. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol Whether this variability meaningfully changes the drug’s effectiveness in a given person is still an open question, but it helps explain why blood levels of naltrexone and its metabolite can differ substantially from one individual to the next.
What Liver Disease Does to Naltrexone Levels
Because naltrexone is used to treat alcohol dependence, a condition that frequently coexists with liver damage, the question of how liver disease affects the drug’s behavior is especially relevant. A study of patients with cirrhosis found that blood exposure to naltrexone (measured as the area under the concentration-time curve) was significantly higher in people with advanced liver disease compared to healthy controls. Exposure to 6-β-naltrexol, by contrast, was not significantly different.6Journal of Hepatology. Effect of liver cirrhosis on the systemic availability of naltrexone in humans Patients with compensated cirrhosis fell somewhere in between.
The important nuance is that the elimination half-life itself did not change among the groups. What changed was how much naltrexone got into the bloodstream in the first place, likely because a damaged liver is less efficient at its first-pass conversion of naltrexone to the metabolite. The result is higher circulating levels of the parent drug and a shift in the ratio of naltrexone to 6-β-naltrexol. Clinicians prescribing naltrexone for patients with known liver disease typically monitor liver function tests, and the drug’s labeling carries a warning about hepatotoxicity at high doses, though the risk at the standard 50 mg dose appears to be low.
The Extended-Release Injectable Form
Oral naltrexone requires a daily pill, and adherence is a persistent challenge in addiction treatment. The extended-release injectable formulation, marketed as Vivitrol, sidesteps this problem by delivering 380 mg of naltrexone in a single intramuscular injection once a month. The pharmacokinetics are entirely different from the oral form. Instead of a rapid peak and decline, the injectable creates a slow, sustained release of naltrexone from a polymer matrix that degrades gradually at the injection site.
A population pharmacokinetic study of the injectable found that naltrexone clearance and volume of distribution were both influenced by body weight and were higher in people with alcohol or opioid dependence than in healthy volunteers. Clearance also declined modestly with age. However, the researchers concluded that none of these covariate effects were clinically meaningful enough to require dose adjustments based on weight, age, sex, health status, smoking, kidney function, or liver function differences.7PubMed. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence In other words, one dose fits most patients. The injectable form maintains therapeutic blood levels for about a month, which is why the injection schedule is every four weeks rather than every day.
When initiating the injectable, clinicians need to ensure the patient is free of opioids to avoid precipitating withdrawal. A standard initiation protocol involves a brief buprenorphine taper followed by an opioid-free period, sometimes supplemented by ascending low doses of oral naltrexone and comfort medications for withdrawal symptoms before the injection is given.8PubMed Central. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial
Age, Genetics, and Individual Variation
The enzyme activity responsible for converting naltrexone to 6-β-naltrexol is not constant across the lifespan. Research examining liver samples from both pediatric and adult donors found that activity increased steadily from birth, peaked during middle childhood around ages two to five, and showed substantial variability across individuals at every age. Genetic variation in specific enzyme forms had a larger effect on biotransformation rates than age itself did.9Drug Metabolism and Disposition. The Impact of Age and Genetics on Naltrexone Biotransformation This is relevant because naltrexone is sometimes used off-label in children for conditions like self-injurious behavior in autism, and understanding that a child’s metabolism may differ from an adult’s helps guide dosing decisions.
The species angle is worth mentioning briefly, because it explains why animal data on naltrexone cannot be straightforwardly applied to humans. In rats, dogs, and mice, 6-β-naltrexol is not a major urinary metabolite of naltrexone, whereas in humans it is the dominant one.10PubMed Central. Disposition of Naltrexone after Intravenous Bolus Administration in Wistar Rats, Low-Alcohol-Drinking Rats and High-Alcohol-Drinking Rats This inter-species difference means that preclinical animal studies of naltrexone’s duration of action can underestimate how long the drug’s effects persist in people, since they miss the metabolite’s extended contribution.
Why Genetics May Shape How Well Naltrexone Works for You
Beyond influencing how quickly the drug is metabolized, genetics may also affect how well naltrexone works at its target. The mu-opioid receptor gene, OPRM1, has a common variant known as A118G. Carriers of the G allele (also called Asp40) appear to respond better to naltrexone treatment for alcohol dependence. In the large COMBINE study, carriers of the Asp40 allele who received naltrexone had an 87 percent rate of good clinical outcomes, compared with about 55 percent for those without the variant. Among patients given placebo, the variant made no difference, suggesting the gene specifically moderates naltrexone’s benefit rather than predicting recovery in general.11JAMA Psychiatry. An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence
A systematic review and meta-analysis pooling data from multiple studies confirmed the pattern: naltrexone-treated patients carrying the G allele had roughly twice the odds of avoiding relapse compared to those without it.12PubMed. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis This does not mean naltrexone is useless for people without the variant; many still benefit. But the finding raises the possibility that genetic testing could someday help clinicians decide whether naltrexone or an alternative medication is the better first choice for a given patient. At the moment, OPRM1 testing before prescribing naltrexone is not standard practice, though some specialty clinics offer it.
Low-Dose Naltrexone and Half-Life Implications
An increasingly discussed off-label use involves taking naltrexone at doses far below the standard 50 mg, typically in the range of 1 to 5 mg. Proponents of low-dose naltrexone (LDN) use it for conditions like fibromyalgia, multiple sclerosis, and certain autoimmune disorders. The proposed mechanism is different from full-dose naltrexone: by briefly and incompletely blocking opioid receptors, low doses may trigger a rebound upregulation of the body’s own endorphin production and modulate immune signaling.
Half-life matters here in a specific way. At 1 to 5 mg, blood levels of naltrexone are much lower and clear faster, meaning the window of receptor blockade is short, perhaps only a few hours. That brief blockade is actually the point. The theory depends on the drug wearing off quickly enough that the rebound effect kicks in before the next dose. If the half-life were much longer, or if the dose were higher, the blockade would be too sustained to produce the desired effect. This is why LDN is taken at bedtime: the drug blocks receptors briefly during the night, wears off by morning, and the hypothesized endorphin surge follows.2PubMed Central. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization Evidence for LDN’s efficacy remains limited and somewhat preliminary for most of these conditions, but it is a growing area of research where the drug’s pharmacokinetic profile is central to the treatment rationale.
What the Half-Life Means for Emergency Pain Management
One practical scenario where naltrexone’s half-life becomes urgent is when a person taking it needs emergency opioid-based pain relief after surgery or trauma. Because the drug blocks opioid receptors, standard doses of morphine or fentanyl will have little or no effect. The receptor blockade from oral naltrexone at standard doses persists well beyond the 4-to-13-hour plasma half-life range. As noted earlier, receptor occupancy in the brain has a half-time measured in days, not hours.
For someone on daily oral naltrexone who stops taking it, clinicians generally expect significant receptor availability to return within about 72 hours, though this varies. For someone who recently received the extended-release injection, the situation is more complicated, since the depot continues releasing naltrexone for weeks. In either case, emergency departments managing acute pain in these patients often turn to non-opioid approaches first: regional nerve blocks, ketamine, acetaminophen, and nonsteroidal anti-inflammatory drugs. If opioids are absolutely necessary, much higher than usual doses may be required, and close monitoring for respiratory depression is essential as the blockade wanes unevenly. This is a scenario where a simple number for “half-life” falls short of capturing the clinical reality, which hinges on receptor-level persistence rather than blood concentrations.
Differences Between Humans and Lab Animals
Researchers who develop naltrexone-based treatments often work first in animal models, and the species differences in metabolism create a genuine translational challenge. In rats, the dominant metabolic pathways produce different products than in humans, and 6-β-naltrexol barely shows up in rodent urine.10PubMed Central. Disposition of Naltrexone after Intravenous Bolus Administration in Wistar Rats, Low-Alcohol-Drinking Rats and High-Alcohol-Drinking Rats Since 6-β-naltrexol is a major contributor to opioid blockade in people, animal studies that measure naltrexone’s duration of action may systematically underestimate how long the drug’s effects last in humans. This gap has practical consequences for drug development: a new naltrexone formulation that looks short-acting in rodent studies might turn out to have a substantially longer effect in people once the metabolite is taken into account.
The discrepancy also complicates abuse-deterrent formulation research, where scientists try to design drug combinations that prevent opioid misuse. If the naltrexone component degrades differently in human livers than in the animal model used for preclinical testing, assumptions about how long the protective blockade lasts can be off by a meaningful margin. This is one reason why human pharmacokinetic studies remain the gold standard before any naltrexone-based product reaches the market.